ORIGINAL ARTICLE

Anaplastic Lymphoma Kinase (ALK) Rearrangement of Lung Adenocarcinoma among North Sumatera Population

Muhammad Yusuf Adira Putra[1]* (iD) , **Noni Novisari Soeroso**[1] (iD) , **Elisna Syahruddin**[2] (iD) , **Evlina Suzanna**[3] (iD) , **Dina Afiani**[1] (iD) , **Taufik Ashar**[2] (iD) , **Darren Wan-Teck Lim**[3] (iD)

[1]Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
[2]Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
[3]Dharmais National Cancer Center Hospital, Jakarta, Indonesia.
[4]Faculty of Public Health, Universitas Sumatera Utara, Medan, Indonesia.
[5]Division of Medical Oncology, National Cancer Centre Singapore/Duke-NUS Medical School, Singapore.

ARTICLE INFO

ABSTRACT

Introduction: Lung cancer is a malignancy of the lung parenchyma or bronchi. Molecular targeted therapy directed at oncogene driver mutations, such as anaplastic lymphoma kinase (ALK), improves the prognosis of patients with non-small cell lung carcinoma (NSCLC). This study aimed to determine the characteristics of lung adenocarcinoma patients and the prevalence of ALK rearrangement among the North Sumatra population.

Methods: This descriptive study used data from patients' formalin-fixed paraffin-embedded (FFPE) ALK examination results and medical records. The laboratory analyzed the patient's FFPE for ALK fusion protein expression using the VENTANA anti-ALK (D5F3) procedure to determine the prevalence of ALK rearrangement.

Results: Of the 34 subjects, it was revealed that the characteristics of lung adenocarcinoma patients were 18 patients aged >60 years old (52.9%), 26 male patients (76.4%), and 24 heavy smoker patients (70.6%). Based on the pathological tumor-node-metastasis (pTNM) stage, most samples were classified as stage IVA, with 24 cases (70.6%) showing the highest metastases to the pleura. There were 2 cases of ALK mutations obtained through immunohistochemical examination with a percentage of 5.8%.

Conclusion: There are relatively few ALK rearrangement mutations in lung adenocarcinoma patients without screening. Additional research is needed to ascertain the distribution of lung adenocarcinoma patient characteristics associated with a higher prevalence of ALK rearrangement mutations.

INTRODUCTION

Lung cancer is a malignancy or tumor originating from the lung parenchyma or within the bronchi. Globally, lung cancer cases and deaths continue to increase. Lung cancer has been the most frequently diagnosed cancer for decades. It remains the most common cancer diagnosis in males, with an estimated 1.37 million people diagnosed in 2018.[1]

Lung cancer can be divided into two major types, namely non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). The most common type of lung cancer is NSCLC, around 85% of all lung cancers. Non-small cell lung carcinoma has several subtypes, including squamous cell carcinoma (epidermoid carcinoma) at 20%, adenocarcinoma at 38.5%, and large cell carcinoma at 2.9%. Meanwhile, SCLC is the highest malignant tumor originating from cells that have neuroendocrine-like characteristics and accounts for 15% of lung cancer cases.[2,3]

Recent research on molecular targeted therapy directed at driver oncogene mutations, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), rearrangement of c-ros oncogene 1 (ROS1), rearranged during transfection 1 (RET1), neurotrophic receptor tyrosine kinase 1 (NTRK1), and Kirsten rat sarcoma viral oncogene (KRAS), improves the prognosis of patients with NSCLC.[4] A previous study showed a high proportion of EGFR mutations in lung adenocarcinoma, reaching 44%, and KRAS

48

J. Respi. January 2025, Vol. 11 (01); 47-53

mutations were not found in the North Sumatra population.[5] There is no data on ALK in North Sumatra, and the global incidence rate is 2-7%.[6]

Anaplastic lymphoma kinase is one of the oncogenes that is being researched extensively. The ALK gene is located on chromosome 2, area 2p23.2-p23.1. As an oncogene, ALK is expressed in several specific areas. When ALK fusion occurs, the formation of dimers from the ALK fusion will cause activation of the ALK protein kinase area, which plays an important role in the tumorigenic process. Partner proteins will control fusion behavior, such as expression and activation levels, and then these cells will proliferate, survive, differentiate, and migrate, ultimately leading to cancer.[7]

Anaplastic lymphoma kinase examination is performed at the molecular level to detect the presence of fusion protein expression. Its rearrangements can be detected using a variety of methods. The most frequently used methods are ALK fluorescence in situ hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR), and ALK immunohistochemistry (IHC). Further evidence of novel methods, such as next-generation sequencing (NGS) and liquid biopsy, may, in the future, change the standard for ALK testing. Patients who are ALK-positive are candidates for therapy with ALK inhibitors.[8]

The presence of the ALK fusion protein and the ALK tyrosine kinase activity is a therapeutic target in all ALK-rearranged cancers. In addition, because ALK is not widely expressed in adult human tissue, few toxic effects would occur if ALK function were inhibited. The first ALK inhibitor introduced in the therapy of ALK-dependent NSCLC was crizotinib, a potent ALK tyrosine kinase inhibitor molecule. The toxicity, resistance, and limitations of crizotinib led to the study of second- and third-generation ALK inhibitors.[7]

Clinical trials for several second- and third-generation ALK inhibitors are ongoing or completed. Secondary resistance mutations discovered in patients receiving crizotinib therapy can be inhibited by second-generation inhibitors, including ceritinib, alectinib, and brigatinib. The majority of these inhibitors exhibit activity that prevents resistance to crizotinib. Compared to crizotinib, second-generation ALK inhibitors are more effective in the central nervous system and have a higher affinity for the ALK fusion gene. The Food and Drug Administration (FDA) has approved these second-generation inhibitor agents for patients who cannot tolerate crizotinib or continue developing disease progression.[9]

The only third-generation ALK inhibitor currently available is lorlatinib (PF-06463922). Lorlatinib is a potent and reversible small molecule that inhibits ROS1 and ALK. These third-generation inhibitors are effective against all resistance types discovered to date. Lorlatinib was created to enhance brain penetration and overcome the problem of resistance to first- and second-generation ALK inhibitors.[10]

METHODS

Study Design and Eligibility Criteria

This study used non-probability consecutive sampling to enroll 34 patients with lung adenocarcinoma. It was conducted at several hospitals in Medan, including Haji Adam Malik General Hospital, Prof. Dr. Chairuddin Panusunan Lubis Universitas Sumatera Utara Hospital, and St. Elisabeth Hospital, to collect research subjects with lung cancer that was histopathologically diagnosed with adenocarcinoma. Clinical data were collected from medical records, including age, gender, staging (pathological tumor-node-metastasis/pTNM stage), organ metastases, smoking habits, and ethnicity. Patients' formalin-fixed paraffin-embedded (FFPE) was borrowed from each hospital for ALK rearrangement detection. The inclusion criteria were pathologically confirmed diagnosis of adenocarcinoma (NSCLC), male and female lung cancer patients, and aged ≥18 years old. The exclusion criteria were incomplete medical record data and patients' FFPE or histopathological tissue that was neither acceptable nor insufficient.

Anaplastic Lymphoma Kinase Rearrangement Detection

The procedure for ALK immunohistochemistry (IHC) utilizing a corresponding negative control and the highly sensitive anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (VENTANA Medical Systems Inc., Tucson, AZ, USA) was performed by a specific protocol designed to detect ALK protein expression in FFPE tissue sections. Patients' FFPE tissue was sectioned into thin slices (typically 3-5 µm) and mounted onto positively charged glass slides. The tissue slides were deparaffinized in xylene or a xylene substitute to remove the paraffin wax and stained with hematoxylin and eosin (H&E). A pathologist ensured that there were enough tumor cells to be examined. VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody was applied to the tissue sections. This antibody specifically bonded to the ALK protein in the sample if it was present. All steps were typically performed using a VENTANA automated system.

VENTANA OptiView DAB (diaminobenzidine) chromogen was used as the detection reagent, which produced a brown precipitate at the site of the ALK

protein-antibody complex, making the signal visible under a microscope. The slides were counterstained with hematoxylin, which stained the nuclei of the cells, providing contrast to the DAB staining. A pathologist examined stained tissue sections under a light microscope. Positive staining for ALK was indicated by brown cytoplasmic staining in tumor cells, while negative staining showed no brown signal. A pathologist assessed the intensity and percentage of tumor cells showing ALK expression to determine ALK status. The D5F3 clone often gave a strong binary positive/negative result, making interpretation more straightforward according to the VENTANA anti-ALK (D5F3) IHC Assay clinical scoring algorithm for NSCLC.

Data Analysis

Clinical and demographic information was collected and displayed as percentages and frequencies. Each variable was displayed using univariate analysis. The Statistical Package for the Social Sciences (SPSS) version 24.0 was used for all statistical analyses.

RESULTS

Thirty-four of the 52 participants in this study met the requirements for inclusion and were able to identify their ALK status. Other participants were removed from this study due to missing medical record data or insufficient FFPE for the ALK IHC examination (Figure 1).


Figure 1. Flow chart of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma

According to the study findings, the majority of research subjects were over 60 years old (52.9%), followed by those between 41 and 60 years old (44.2%), and there was only one sample between the ages of 18 and 40 years old (2.9%). In this study, 61 years old was the average age. Gender-wise, the lung adenocarcinoma patients were predominantly males (76.4%). The samples were distributed based on race and ethnicity, with Minang having 9 samples (26.4%) and Batak/Karo having 19 samples (55.8%), the largest group. Only five samples (14.7%) had never smoked, according to the degree of smoking, while 24 samples (70.6%) were heavy smokers. Based on pTNM stage, the research characteristics showed that most lung adenocarcinoma patients (70.6%) were at stage IVA, followed by stage IIIB (8 cases, 23.6%), with no cases at stage IIIA or lower. This study found that 32 cases (94.2%) had negative expression of ALK fusion protein in lung adenocarcinoma, while 2 cases (5.8%) had positive expression. Both ALK-positive subjects were at stage IVA and had pleural metastases (100%).

Table 1. Prevalence of anaplastic lymphoma kinase (ALK) rearrangement

ALK Rearrangement	Total	
	N	%
ALK rearrangement positive (+)	2	5.8
ALK rearrangement negative (-)	32	94.2

50

J. Respi. January 2025, Vol. 11 (01); 47-53

Figure 2. An experienced pathologist evaluated the last portion of the exam. A) & B) Negative anaplastic lymphoma kinase (ALK) immunohistochemistry (IHC) examination results; C) & D) Positive ALK IHC examination results showed strong and diffuse staining.

Table 2. Characteristics of anaplastic lymphoma kinase (ALK) rearrangement mutation samples

Characteristics	ALK Rearrangement		Total (%)
	Positive (%)	**Negative (%)**	
Age			
<40 years old	0 (0)	1 (3.1)	1 (2.9)
41-60 years old	1 (50)	14 (43.8)	15 (44.1)
>60 years old	1 (50)	17 (53.1)	18 (52.9)
Sex			
Male	1 (50)	24 (75)	25 (73.5)
Female	1 (50)	8 (25)	9 (26.5)
Smoking status			
Never smoker	0 (0)	5 (15.6)	5 (14.7)
Mild smoker	0 (0)	4 (12.5)	4 (11.8)
Moderate smoker	0 (0)	1 (3.1)	1 (2.9)
Heavy smoker	2 (100)	22 (68.8)	24 (70.6)
pTNM stage			
IIIB	0 (0)	8 (25)	8 (23.5)
IIIC	0 (0)	1 (3.1)	1 (2.9)
IVA	2 (100)	22 (68.8)	24 (70.6)
IVB	0 (0)	1 (3.1)	1 (2.9)
Organ metastases			
No metastases	0	9 (28.1)	9 (26.5)
Pleura	2 (100)	20 (62.5)	22 (64.7)
Hepar	0	2 (5.9)	2 (5.9)
Brain	0	2 (5.9)	2 (5.9)
Others (bone, axilla, colli, pericardium, vertebra, plica vocalis)	0	6 (17.6)	6 (17.6)
Total	2 (100)	32 (100)	34 (100)

pTNM: pathological tumor-node-metastasis

DISCUSSION

Anaplastic lymphoma kinase rearrangement is one of the many traits and molecular involvements of lung cancer. In this study, lung adenocarcinoma cases with ALK mutations were found in 2 cases (5.8%), and ALK was found to be negative in 32 cases (94.2%). A study by Koivunen et al. (2008) had the same trend as the NSCLC sample, in which the ALK fusion gene was identified in 1% of Americans and 3% of Korean patients.[11] A previous study in Hong Kong showed that the frequency of ALK in NSCLC was 4.9%.[12] None of the patients had ever been examined for EGFR mutations.[12] In that study, EGFR positivity was later discovered in 46.9% of samples.[12] This suggests that among NSCLC patients who were not previously screened, echinoderm microtubule-associated protein-like 4/EML4-ALK rearrangements were uncommon (1–5%). According to Shaw, *et al.* (2009), up to 22% of screened adenocarcinoma patients with a history of non-smokers or light smokers had ALK mutations.[13] Ren, *et al.* (2012) showed that the prevalence of lung adenocarcinoma with wild-type EGFR mutation and EML4-ALK rearrangement could reach 32% in non-smokers.[14] It is in line with a study by Heriyanto, *et al.* (2020), which demonstrated that the prevalence of ALK in lung adenocarcinoma cytology specimens with negative EGFR mutations was 20%.[15]

Ahyati, *et al.* (2019) showed that the sample of adenocarcinoma patients aged 18-40 years old was 7 cases (18.4%), 41-60 years old was 17 cases (44.7%), and >60 years old was 14 cases (36.8%).[16] It is slightly different from this study, which showed that most of the sample (18 cases, 52.9%) were 60 years old or older. According to Fauziah (2019), from 2012 to 2017, most patients diagnosed with lung adenocarcinoma at the Department of Anatomical Pathology, Dr. Hasan Sadikin General Hospital, were aged >40 years old (90%).[17] That study is consistent with this study, which found only 1 instance (2.9%) involving a patient younger than 40 years old.

A meta-analysis of the characteristics of lung adenocarcinoma patients in Indonesia conducted by Purnawati, *et al.* (2019) found that the age of lung cancer patients varied.[18] Of the 19 journals that gathered data on the average age of lung cancer patients, 17 reported that most of these patients were older than 40 years old, and 2 other journals reported that the majority were younger than 40 years old.[18] Most lung cancer cases start in adulthood, according to the pathogenesis theory of the disease's course, supported by the 17 journals.[18] This was brought on by early-life prolonged exposure to carcinogenic substances and aging-related immune system deterioration, which promoted carcinogenesis.[18]

The research subject's characteristics indicated their degree of smoking, with 24 samples (70.6%) being heavy smokers. The primary cause of all forms of lung cancer is smoking. It is widely acknowledged that smoking causes lung cancer and that the length of a smoker's smoking history is the most significant predictor of their risk of developing lung cancer. Lung cancer is not caused by nicotine, although it can lead to cigarette addiction. The primary carcinogen found in cigarettes is continuous exposure to tar.[19] However, according to Fauziah (2019), 75% of the lung cancer patients diagnosed between 2012 and 2017 were non-smokers, whereas the remaining patients smoked.[17] The high incidence of lung adenocarcinoma in non-smoking patients is related to the subtype of lung adenocarcinoma.[19]

Arumsari, *et al.* (2019), Aktalina (2019), and Soeroso, *et al.* (2021) gathered information on lung cancer patients with a higher Brinkman index severity.[20–22] From these three studies, it may be concluded that smoking increases the risk of lung cancer.[20–22] According to data on the distribution of cancer stages, most study participants were in stage IV. Sanchez-Lara, *et al.* (2012) yielded similar results, supporting the theory that the prevalence of advanced-stage lung cancer was higher than that of the early stage because the latter was typically characterized by non-specific symptoms or no symptoms at all, making an early diagnosis difficult.[23,24]

This study used FFPE tissue samples from biopsy, whether transthoracic or transbronchial. Tissue biopsy is the gold standard for diagnosing NSCLC and identifying histological subtypes. It is also used for some predictive biomarker assessment using molecular biology testing (one gene sequencing and NGS methods), IHC (like immunostaining for programmed death-ligand 1/PD-L1 and ALK), and FISH (ALK, ROS1, and mesenchymal-epithelial transition factor receptor/MET). Furthermore, a tissue biopsy typically has a higher sensitivity for fusion and copy number variation detection than a liquid biopsy, especially when the tumor fraction in cf-DNA is small (<1%).[25]

Immunohistochemistry examination in pathology practice has been widely used because it is fast, economical, and simple. It has been recommended as an alternative detection method for ALK rearrangement. Immunohistochemistry testing is a suitable and reliable alternative to FISH for detecting ALK-positive NSCLC.[26] The VENTANA ALK (D5F3) CDx Assay was specifically developed to maximize agreement with ALK FISH testing and to enable the use of ALK IHC as a standalone companion diagnostic test to identify

patients with ALK-positive NSCLC eligible for treatment with crizotinib.[27]

Anaplastic lymphoma kinase rearrangement is affiliated with advanced stages at which manifestations appear. In addition, patients with ALK-positive were observed to have a special pattern of disease spread. In one report of advanced-stage patients, ALK rearrangement was significantly associated with pericardial, pleural, and hepatic metastases compared with ALK-negative patients.[28] The patients in this study who tested positive for ALK had metastases to the pleura and were in stage IVA.

CONCLUSION

Lung adenocarcinoma patients in this study were mostly males, older than 60 years old, and heavy smokers. According to immunohistochemical analysis, 5.8% of lung adenocarcinoma cancer patients had an ALK rearrangement mutation. There are relatively few ALK rearrangement mutations in lung adenocarcinoma patients without screening. Additional research is required to ascertain the characteristics distribution of lung adenocarcinoma patients that are associated with a higher prevalence of ALK rearrangement mutations.

Conflict of Interest
The authors declared there is no conflict of interest.

Authors' Contributions
Concept or idea, design, and research substance: MYAP, NNS, ES, ES, DA, and DWTL. Collected data by searching the literature and obtained information: MYAP and NNS. Data analysis and research methodology: MYAP, NNS, and TA. Manuscript preparation, editing, and review: MYAP, NNS, ES, ES, DA, TA, and DWTL. All authors contributed and approved the final version of the manuscript.

REFERENCES
1. World Health Organization (WHO). *Cancer*. Geneva, https://www.who.int/health-topics/cancer#tab=tab_1 (2022).
2. Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. Treasure Island (FL), 2025. [PubMed]
3. Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. *Cancer Epidemiol Biomarkers Prev* 2019; 28: 1563–1579. [PubMed]
4. Di Marco MV, Voena C. Review: Biological Implications of Oncogenic Rearrangements in Non-Small Cell Lung Cancer. *Precis Cancer Med* 2022; 5: 1–17. [Journal]
5. Syahruddin E, Wulandari L, Sri Muktiati N, et al. Uncommon EGFR Mutations in Cytological Specimens of 1,874 Newly Diagnosed Indonesian Lung Cancer Patients. *Lung Cancer (Auckland, NZ)* 2018; 9: 25–34. [Journal]
6. Chen MF, Chaft JE. Early-Stage Anaplastic Lymphoma Kinase (ALK)-Positive Lung Cancer: A Narrative Review. *Transl Lung Cancer Res* 2023; 12: 337–345. [PubMed]
7. Sinjab A, Rahal Z, Kadara H. Cell-by-Cell: Unlocking Lung Cancer Pathogenesis. *Cancers (Basel)*; 14. Epub ahead of print July 2022. [PubMed]
8. Kozuma Y, Toyokawa G, Seto T. ALK Testing Methods: Is There a Winner or Loser? *Expert Rev Anticancer Ther* 2019; 19: 237–244. [Journal]
9. Zhao Z, Verma V, Zhang M. Anaplastic Lymphoma Kinase: Role in Cancer and Therapy Perspective. *Cancer Biol Ther* 2015; 16: 1691–1701. [PubMed]
10. Basit S, Ashraf Z, Lee K, *et al*. First Macrocyclic 3rd-Generation ALK Inhibitor for Treatment of ALK/ROS1 Cancer: Clinical and Designing Strategy Update of Lorlatinib. *Eur J Med Chem* 2017; 134: 348–356. [ScienceDirect]
11. Koivunen JP, Mermel C, Zejnullahu K, *et al*. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. *Clin Cancer Res* 2008; 14: 4275–4283. [PubMed]
12. Wong DWS, Leung ELH, So KKT, *et al*. The EML4-ALK Fusion Gene is Involved in Various Histologic Types of Lung Cancers from Nonsmokers with Wild-Type EGFR and KRAS. *Cancer* 2009; 115: 1723–1733. [PubMed]
13. Shaw AT, Yeap BY, Mino-Kenudson M, *et al*. Clinical Features and Outcome of Patients with Non-Small-Cell Lung Cancer who Harbor EML4-ALK. *J Clin Oncol* 2009; 27: 4247–4253. [PubMed]
14. Ren S, Chen X, Kuang P, *et al*. Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never-Smoker Women with Pulmonary Adenocarcinoma. *Cancer* 2012; 118: 5588–5594. [PubMed]
15. Heriyanto DS, Trisnawati I, Kumara EG, *et al*. The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. *Pulm Med* 2020; 2020: 3578748. [Journal]
16. Ahyati SN, Oktaviyanti IK, Yuliana I. Hubungan Jenis Kelamin dan Riwayat Merokok dengan Mutasi Gen EGFR pada Penderita Kanker Paru Tipe Adenokarsinoma. *Homeostasis* 2019; 2: 1–8. [Journal]

53

J. Respi. January 2025, Vol. 11 (01); 47-53

17. Fauziah K. *Karakteristik Pasien Adenokarsinoma Paru Berdasarkan Faktor Risiko dan Derajat Histopatologi di Departemen Patologi Anatomi RSUP Dr. Hasan Sadikin Bandung Periode 2012-2017*. Universitas Jenderal Achmad Yani, http://repository.unjani.ac.id/repository/efd4d797f937a28ae57ef656f8aab5ce.pdf (2019).

18. Purnamawati P, Tandrian C, Sumbayak EM, *et al*. Analisis Kejadian Kanker Paru Primer di Indonesia pada Tahun 2014-2019. *J Kedokt Meditek* 2021; 27: 164–172. [Journal]

19. Nicholson AG, Tsao MS, Beasley MB, *et al*. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. *J Thorac Oncol* 2022; 17: 362–387. [PubMed]

20. Soeroso NN, Ananda FR, Pradana A, *et al*. The Absence of Mutations in the Exon 2 KRAS Gene in Several Ethnic Groups in North Sumatra May Not the Main Factor for Lung Cancer. *Acta Inform Med* 2021; 29: 108–112. [PubMed]

21. Aktalina L. Hubungan Tingkatan Berat Merokok (Indeks Brinkman) dan Kejadian Kanker Paru. *J Kedokt Methodist* 2019; 12: 47–50. [Journal]

22. Arumsari D, Artanti KD, Martini S, *et al*. The Description of Smoking Degree based on Brinkman Index in Patients with Lung Cancer. *J Berk Epidemiol* 2019; 7: 249–256. [Journal]

23. Sánchez-Lara K, Turcott JG, Juárez E, *et al*. Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response with Quality of Life and Prognosis in Patients with Advanced Non-Small-Cell Lung Cancer: A Prospective Study. *Nutr Cancer* 2012; 64: 526–534. [PubMed]

24. Jusuf A, Wibawanto A, Icksan A, *et al*. *Kanker Paru Jenis Karsinoma bukan Sel Kecil: Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta, 2016.

25. Hofman P. Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives. *Cancers*; 16. Epub ahead of print 2024. [Journal]

26. Paolini D, Tiseo M, Demma F, *et al*. Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect. *Clin Lung Cancer* 2018; 19: e735–e743. [ScienceDirect]

27. Thorne-Nuzzo T, Williams C, Catallini A, *et al*. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. *J Thorac Oncol* 2017; 12: 804–813. [ScienceDirect]

28. Doebele RC, Lu X, Sumey C, *et al*. Oncogene Status Predicts Patterns of Metastatic Spread in Treatment-Naive Nonsmall Cell Lung Cancer. *Cancer* 2012; 118: 4502–4511. [PubMed]